SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Alnylam Pharmaceuticals Files Clinical Trial Application to Initiate a Phase I Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)